CING cingulate.com: Forward P/S Multiple

Public company logo of cingulate.com (CING)

The forward P/S dynamics allow for a valuation of Cingulate Inc. (CING) based on synergies with research centers in the development of ADHD therapies. However, geopolitical logistics disruptions are hindering international trials, and a lack of internal cash flows leaves the company dependent on investments. Currently, this metric stands at , which helps objectively correlate market capitalization with expected revenue without reporting lags.

Cingulate Inc - CING Market Cap to Expected Sales Ratio (period 07/04/2022 - 11/13/2026)

Analytical breakdowns and data insights for company cingulate.com (CING)

- market price and analyst price targets:
Price Chart Cingulate|CING - Average Forecast Price
- company stock capitalization data:
Market Capitalization Cingulate Inc.|CING - Real Price to Acquire Entire Company
- issuer book value statistics:
Book Value per Share Cingulate|CING - Book Valuation of Business|Market Value to Book Value Ratio cingulate.com|CING - Total Business Assets
- debt level and financial liquidity data:
Total Debt to Capital Cingulate Inc.|CING - Long-Term Indebtedness to Equity|Short-Term Debt to Equity Ratio Cingulate|CING - Company Aggregate Debts|Debt to Book Capitalization Ratio Cingulate Inc.|CING - Company Long-Term Debt|Company Short-Term Debts Cingulate|Quick Liquidity Indicator cingulate.com
- financial results and valuation multiples details:
CING - Profit After Payment of Taxes|Projected Future Earnings Cingulate Inc.|CING - Market Cap to Earnings|Projected Price to Earnings Cingulate|CING - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Cingulate Inc.|CING - Operating income before deduction of amortization|Earnings per share for the last twelve months Cingulate|CING - Earnings per share for the last 12 months|Quarterly EPS earnings growth cingulate.com|CING - Net earnings per share growth this year|Expected earnings per share growth for next year Cingulate Inc.
- sales volume and revenue indicators:
CING - Company Gross Revenue|Projected Sales Volume Cingulate|CING - Market Cap to Revenue|Forward P/S Multiple Cingulate Inc.
Fundamental company analysis:CING (Cingulate Corp)
Product sample of Cingulate Inc

The licensing prospects for the CTX-1301 drug for ADHD therapy make the forward revenue multiple a key indicator of market expectations regarding the future cash flows of Cingulate Inc. (CING). This chart compares current market capitalization with expected forward sales, allowing investors to perform a real-time assessment of the premium for potential clinical success and the pace of business scaling.

Who Cingulate Inc. competes with

Price-to-Projected Revenue Ratio Alkermes ALKS|Avadel Pharmaceuticals PLC (AVDL) - Market Cap to Future Revenue Ratio|atai Life Sciences Corp - Forward P/S Multiple|GH Research Group (GHRS) - Forward Price-to-Revenue Multiple|MNMD: Forward P/S Multiple|CMPS - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio LB Pharmaceuticals|Market Cap to Projected Revenue DRUG (Bright Minds Bio)|Forward P/S Multiple VNDA|cybin.com (CYBN) - Projected Price to Revenue|Alto Neuroscience, Inc. - Forward Price-to-Revenue Multiple|Forward P/S Multiple nrxpharma.com NRXP|SILO - Price-to-Projected Revenue Ratio|CPHI: Price-to-Projected Revenue Ratio|CMND: Forward P/S Multiple|Psyence Bio (PBM) - Forward P/S Multiple|Forward Price-to-Revenue Multiple SPRC|SEEL (seelostherapeutics.com) - Price to Expected Revenue Ratio|Forward P/S Multiple VRPX|KRTX - Market Cap to Future Revenue Ratio